| Literature DB >> 1753253 |
P Dal-Bianco1, J Maly, C Wôber, C Lind, G Koch, J Hufgard, I Marschall, M Mraz, L Deecke.
Abstract
18 patients who had fulfilled the NINCDS-ADRDA criteria for "possible AD" took part in a clinical study to evaluate the effect of the cholinesterase inhibitor Galanthamine, 30 mg/day. Neuropsychological und social parameters were rated. This open clinical pilot-study showed no statistic significant change in neuropsychological test-results. However after 1 year treatment 6 patients are still taking the drug. According to their care-persons there was a positive changes in competence of everyday-routine and/or in the emotional situation.Entities:
Mesh：
Substances：
Year: 1991 PMID： 1753253 DOI： 10.1007/978-3-7091-9135-4_10
Source DB: PubMed Journal: J Neural Transm Suppl ISSN： 0303-6995